Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 193

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANT RECIPIENTS

Patel, Robin, Snydman, David R., Rubin, Robert H., Ho, Monto, Pescovitz, Mark, Martin, Maureen, Paya, Carlos V. · 1996 · Transplantation

Abstract

Symptomatic cytomegalovirus (CMV*) infection occurs in 8%, 29%, 25%, and 39% of kidney, liver, heart, and heartlung transplant recipients, respectively (1). CMV is transmitted to transplant recipients mainly by the donor organ and to a lesser degree by blood products (2). In the solid organ transplant recipient, CMV is related to: (1) infectious diseases syndromes and organ involvement (lung, liver, gastro-intestinal, retinitis, among others); (2) increased immunosuppression (hence its frequent association with other opportunistic infections, e.g., fungal and Pneumocystis) (3); and (3) although controversial, acute and chronic allograft injury (4, 5). The diagnosis of CMV infection is based on the recognition of cytomegalic inclusion bodies in tissue. In addition, tube cell and shell vial culture techniques are used to detect replicating CMV in body fluids and in tissue. Demonstration of CMV in blood (viremia) or in tissue biopsies is highly correlated with the presence of clinically active or impending infection, whereas isolation of the virus from urine or respiratory secretions is frequently a marker of asymptomatic infection. Direct detection of antigenemia in blood leukocytes of transplant recipients is sensitive and more rapid than the shell vial technique, and provides an early marker of active CMV infection (6, 7). Polymerase chain reaction (PCR) techniques can detect CMV DNA in peripheral blood leukocytes (8), serum or plasma (9), and other clinical specimens, as well as CMV RNA in peripheral blood leukocytes. The clinical usefulness of PCR is currently being evaluated. Risk factor analyses have provided important clues to identify those patients at high risk for symptomatic CMV infection, reflecting in part the pathogenesis of CMV following solid organ transplantation. A lack of cellular and humoral immunity, as defined by the absence of anti-CMV antibodies, places the recipient in the high-risk category upon receiving a CMV seropositive donor's organ or other exogenous source of CMV (e.g., blood transfusion). In addition, antilymphocyte immunoglobulins (antithymocyte globulin, antilymphocyte globulin, OKT3 mAb), used either as induction therapy or for allograft rejection treatment, enhance the rate of symptomatic CMV infection, especially in CMV seropositive individuals (10, 11). Although more information is needed about the biology of CMV, viral load may play an important role in identifying patients at higher risk. For example, the high rate of symptomatic CMV infection in lung and gastrointestinal transplant recipients may reflect the transplantation of a higher latent CMV load contained in a larger amount of tissue with increased endothelial and lymphoid compartments. Thus, prophylactic measures found to be effective for renal transplantation may not apply to lung or gastrointestinal transplantation. Likewise, lessons learned from CMV infection in bone marrow transplantation can be only partially extrapolated to the nonhomogenous field of solid organ transplantation due to differences in pathogenesis. The ideal CMV prophylactic regimen should be characterized as: (1) effective in an oral formulation if frequent administration is required or in an intravenous formulation that can be given at infrequent intervals (i.e., weekly); (2) safe, thus requiring minimal laboratory evaluations and having a wide therapeutic range to avoid monitoring of levels; (3) having minimal interactions with conventional “transplantation” medications; (4) pan virustatic-cidal to cover not only CMV but other herpes family viruses (herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, human herpesvirus 6), with a low chance of inducing antiviral resistance; (5) administered only to patients at risk for symptomatic CMV infection; and (6) cost effective. Based on the current state-of-the-art CMV prophylaxis and treatment, significant advances need to be made in order to achieve the above goals. Current prophylactic approaches vary widely among different transplant programs. Reasons for the discrepancies reflect the absence of large, multicentered, randomized trials. In addition, results of small single-center studies are frequently difficult to reproduce, as differences in endpoints, definitions, viral surveillance (frequency, methodology), type of immunosuppressive regimen, patient populations, and frequency of antilymphocyte antibody treatment are common. More importantly, inherent differences among the type of solid organ transplanted need to be considered. This results in a myriad of prophylactic regimens, many of which may be insufficient or even excessive, from both effectiveness and cost perspectives. This Overview summarizes currently available data addressing the prophylaxis of CMV, clarifies key points that should serve for the design of rational prophylaxis regimens utilizing current antiviral agents, and outlines future alternative strategies as new agents and approaches become available. SERONEGA

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00007890-199605150-00001

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 193

Metadata

Authors
Patel, R., Snydman, D. R., Rubin, R. H., Ho, M., Pescovitz, M., Martin, M., & Paya, C. V.
Venue
Transplantation
Published
1996-05
Volume
61
Issue
9
Pages
1279-1289
ISSN
0041-1337 (ISSN-L)
OpenAlex
W1984734334
Cited by
193
References
1
FWCI
18.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANT RECIPIENTS. https://app.cochat.ai/papers/10.1097/00007890-199605150-00001
The paper
Patel, R., Snydman, D. R., Rubin, R. H., Ho, M., Pescovitz, M., Martin, M., & Paya, C. V. (1996). CYTOMEGALOVIRUS PROPHYLAXIS IN SOLID ORGAN TRANSPLANT RECIPIENTS. Transplantation. https://doi.org/10.1097/00007890-199605150-00001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.